Search
Research
Molecular surveillance of true nontypeable haemophilus influenzae: An evaluation of pcr screening assaysUnambiguous identification of nontypeable Haemophilus influenzae (NTHi) is not possible by conventional microbiology. Molecular characterisation of...
Research
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasiaWe report vaccine efficacy against CIN3+ and adenocarcinoma in situ (AIS) in the end-of-study analysis of PApilloma TRIal against Cancer In young Adults.
Research
A phase 3, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety and tolerability of V114 in healthy infants (PNEULINK)Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
Research
The burden of rotavirus-related illness among young children on the Australian health care systemTo provide estimates of the annual number and cost of hospital admissions, emergency department (ED) visits and general practitioner (GP) visits...
Research
Immunogenicity and safety of a combined Haemophilus influenzae type b-NeisseriaNeisseria meningitidis serogroups B, C, and Y cause most meningococcal disease in industrialized countries...
Research
Safety and Immunogencity of a Prototype Adjuvanted Inactivated Split-Virus Influenza A (H5N1) Vaccine in Infants and ChildrenHighly pathogenic avian influenza A virus (H5N1) is a leading candidate for the next influenza pandemic, and infants and children may play an important role...
News & Events
Whooping cough vaccine could be a new weapon in the fight against food allergiesResearchers from The Kids Research Institute Australia and Curtin University will use a $3.9 million grant from the National Health and Medical Research Council to investigate whether a type of whooping cough vaccine could provide bonus protection against food allergies and eczema.
Research
Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers Aged 18-36 monthsA bivalent, recombinant, factor H-binding protein (rLP2086) vaccine was developed to protect against invasive Neisseria meningitidis serogroup B (MnB) in...
Research
A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults:Neisseria meningitidis is a leading cause of meningitis and septicaemia, but a broadly-protective vaccine against endemic serogroup B disease is not licensed...
Research
Can linked emergency department data help assess the out-of-hospital burden of acute lower respiratory infectionsThere is a lack of data on the out-of-hospital burden of acute lower respiratory infections (ALRI) in developed countries.